Healthcare-Specific Reps, Warranties, and Indemnification

Introduction

Healthcare purchase agreements contain a layer of representations and warranties that has no equivalent in other sectors. While every M&A transaction includes standard reps (financial statements, tax compliance, material contracts, litigation), healthcare transactions add 10-15 additional representations specific to the sector's regulatory environment. These healthcare-specific reps protect the buyer against risks that are uniquely severe in healthcare: fraud and abuse liability with treble damages, regulatory enforcement actions that can shut down operations overnight, HIPAA breaches with class action exposure, and compliance failures that can result in exclusion from federal healthcare programs.

Federal Program Participation

The seller represents that the target is properly enrolled in all federal healthcare programs (Medicare, Medicaid, TRICARE, CHIP), that no provider or employee has been excluded from federal programs (checked against the OIG's LEIE database), that no program integrity investigations are pending, and that there are no outstanding overpayment obligations. Exclusion from federal programs is effectively a death sentence for most healthcare businesses because Medicare and Medicaid revenue often represents 30-60%+ of total revenue.

Fraud and Abuse Compliance

Fundamental Representation

A representation designated as "fundamental" in the purchase agreement, which means it receives extended survival (typically until the statute of limitations expires, often 5-7 years) and is not subject to the general indemnification cap. In healthcare transactions, fraud-and-abuse reps, federal program participation reps, and licensing reps are typically designated as fundamental because the underlying risks are both severe (treble damages, program exclusion) and latent (violations may not surface for years). Designating a rep as fundamental ensures the buyer has recourse for the full survival period, even after the general rep survival period (typically 12-18 months) has expired.

The fraud and abuse reps in healthcare transactions are among the most detailed provisions in the entire purchase agreement. The seller typically represents that:

Professional Licensing and Credentialing

The seller represents that all providers (physicians, nurse practitioners, physician assistants) hold current, unrestricted licenses to practice in all states where they provide services, maintain active hospital privileges where applicable, and are credentialed with all payers through which they bill. Discovering post-closing that a key provider's license has lapsed, is restricted, or is under investigation can impair both revenue (the provider cannot bill) and regulatory standing.

HIPAA Privacy and Security

340B Program Compliance

For targets participating in the 340B Drug Pricing Program, specific reps address program eligibility, covered entity status, contract pharmacy arrangements, compliance with the prohibition on duplicate discounts, and the target's 340B compliance program. Given the complexity of 340B rules and the increasing enforcement attention from HRSA, these reps have become more detailed in recent years.

DEA Registration

Targets that handle controlled substances represent that all DEA registrations are current, that controlled substance handling procedures comply with DEA regulations, and that no DEA investigations or enforcement actions are pending. For pain management practices, addiction treatment facilities, and pharmacies, DEA compliance is a high-scrutiny diligence area.

Escrow Size

Healthcare transactions typically use larger indemnification escrows than standard M&A transactions: 10-20% of the purchase price versus 5-10% in other sectors. The larger escrow reflects the greater severity and latency of healthcare-specific risks. A fraud and abuse violation discovered 3 years post-closing can generate FCA liability of several hundred million dollars, and the escrow must be sized to provide meaningful buyer protection against this tail risk.

Survival Periods

As discussed above, healthcare-specific reps carry survival periods of 3-7 years, well beyond the 12-18 month survival typical for general representations. The extended survival reflects the reality that many healthcare compliance issues are latent: a Stark Law violation in physician compensation arrangements may not surface until a disgruntled employee files a qui tam action years after the arrangement began.

Special Indemnities

In addition to general indemnification, healthcare transactions often include "special indemnities" for specific identified risks that fall outside R&W insurance coverage. These might include indemnification for a known but unresolved government investigation, a specific payer contract dispute, or a pending qui tam action that was disclosed during diligence. Special indemnities are typically uncapped (or subject to a separate, higher cap) and survive for the duration of the underlying risk.

The next article covers payer contract assignment and the managed care transition challenges unique to healthcare transactions.